Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of VX-407 in healthy volunteers
NCT06345755Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of VX-407 in autosomal dominant polycystic kidney disease (ADPKD) (6 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Adverse Events at Day 22. Started Apr 2024; status: completed.
02
Drugs
VX-407
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06345755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345755.